A 42-year-old woman is referred after her brother was diagnosed with medullary thyroid carcinoma at age 38. She is asymptomatic but reports two paternal uncles who died of thyroid cancer in their 40s. There is NO family history of pheochromocytoma, hypertensive crises, or kidney stones. Thyroid ultrasound shows two small hypoechoic nodules with microcalcifications. Serum calcitonin is mildly elevated at 85 pg/mL (normal <10), CEA is normal, and plasma free metanephrines are normal on two occasions. Genetic testing reveals the mutation shown at **B** in the diagram. Based on this genetic finding and clinical presentation, what is the MOST appropriate next step in management?
A. Parathyroid surgery after confirming hyperparathyroidism on biochemical screening
B. Observation with annual calcitonin monitoring and pheochromocytoma screening, as V804M carries very low lifetime risk
C. Immediate initiation of vandetanib as first-line therapy for presumed metastatic disease
D. Prophylactic total thyroidectomy with central neck dissection now, given elevated calcitonin and confirmed RET V804M mutation
Explanation
Why "Prophylactic total thyroidectomy with central neck dissection now, given elevated calcitonin and confirmed RET V804M mutation" is right
The RET V804M mutation shown at B is the hallmark of Familial Medullary Thyroid Carcinoma (FMTC), a clinical variant of MEN2A characterized by isolated MTC in ≥4 family members with NO pheochromocytoma or hyperparathyroidism. According to ATA Guidelines, V804M is classified as MODERATE risk. Although FMTC typically presents later (5th–6th decade) than classical MEN2A (C634Y mutations), this patient has already developed elevated calcitonin (85 pg/mL) and imaging evidence of thyroid nodules, indicating early disease. The presence of elevated calcitonin is the trigger for definitive surgical intervention. Total thyroidectomy with central neck dissection is the standard of care when calcitonin is elevated, as it offers the best chance for cure before metastatic spread occurs.
Why each distractor is wrong
Observation with annual calcitonin monitoring and pheochromocytoma screening, as V804M carries very low lifetime risk: While V804M does carry moderate rather than high risk, and pheochromocytoma screening is appropriate, observation is inappropriate once calcitonin is elevated. Elevated calcitonin indicates active disease and mandates thyroidectomy, not surveillance alone.
Immediate initiation of vandetanib as first-line therapy for presumed metastatic disease: Vandetanib and other tyrosine kinase inhibitors are reserved for unresectable or metastatic disease, not for localized disease with elevated calcitonin. Surgery remains first-line when disease is still potentially curable.
Parathyroid surgery after confirming hyperparathyroidism on biochemical screening: This patient's serum calcium and PTH are normal, and there is no family history of hyperparathyroidism. FMTC, by definition, does NOT include primary hyperparathyroidism. Parathyroid surgery is not indicated.
High-YieldNEET PG
RET V804M (FMTC) = moderate-risk MTC without pheochromocytoma or hyperparathyroidism; elevated calcitonin mandates thyroidectomy + central neck dissection, not observation or medical therapy.
ATA Guidelines on MTC
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
